Q3 2022 Results

Company overview Financial review 2022 priorities Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials Cardiovascular Immunology Neuroscience Oncology branaplam-mRNA splicing modulator NCT05111249 VIBRANT-HD (CLMI070C12203) Indication Phase Huntington's disease Phase 2B 1. Reduction (%) of mHTT protein in cerebrospinal fluid (CSF) Patients 75 Primary Outcome Measures Arms Intervention Target Patients 2. Number of treatment emergent adverse events and serious adverse events Arm 1: Experimental; Branaplam 56 mg oral solution once weekly Arm 2: Experimental; Branaplam 112 mg oral solution once weekly Arm 3: Experimental; (C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly Arm 4: Placebo; Matching placebo oral solution once weekly Participants with early manifest Huntington's Disease Read-out Milestone(s) 2025 Publication TBD 60 Investor Relations | Q3 2022 Results References Abbreviations Other NOVARTIS | Reimagining Medicine

View entire presentation